Anaphylm Resubmission Nears with Clean Human Factors and PK Data
Aquestive prepares to file its epinephrine film NDA, backed by improved usability and differentiated pharmacodynamics, while advancing AQST-108.
AQST · Earnings Call · 2026-08-12
Milestone: Resubmission on Track
After months of focused work, Aquestive has completed the studies needed to support the Anaphylm NDA resubmission, and management confirms it remains on track to file before the end of Q3. The human factors validation study showed a dramatic improvement: “we had only 1 participant show difficulty and no one tore the film” — Daniel Barber, President and Chief Executive Officer · 2026-08-12 versus 26 difficulty events and 6 film tears previously. The PK study also met expectations, with no statistical difference between clinician- and self-administration. Even an off-label top-of-tongue administration produced clinically meaningful pharmacodynamic responses, a reassuring safety net for prescribers.
we believe we are easier to carry than auto-injectors... and have shown in our studies meaningful clinical differentiation from the auto-injector on time to maximum concentration and on change from baseline blood pressure.
Clinical Differentiation as a Payer Wedge
The company is leaning into clinical differentiation as the primary lever for payer coverage, rather than simply being a needle-free option. As Matt Greenhawt described, the data provide real reassurance: “if you do (misadminister), even in the setting of low resulting PK, the resulting PD is overlapping with the same magnitude of change that we saw when we used EpiPen in our pivotal study.” — Matthew Greenhawt, Unknown · 2026-08-12 This narrative is supported by the epinephrine rescue market growing roughly 6% annually and a potential $1–2B branded opportunity. The commercial team remains focused on allergist focused launch preparation, with a disciplined and scalable approach to sales and marketing.
Financial and Strategic Position
Aquestive ended Q2 with $98.5M in cash and completed a new $150M debt facility with Oaktree, extending its interest-only period and lowering cost of capital. Total revenue increased 38% y/y to $13.8M, driven by Suboxone manufacturing and Zevra royalties. The latest reported revenue of $14M is up 66% year-over-year, reflecting strong base business momentum. The company's Human Factors work and the growing interest in atopic derm for AQST-108 highlight a broadening pipeline beyond the lead asset.
Since the CRL, the team has maintained its sense of urgency, as evidenced by earlier remarks: “We have a great team here who has the study designs completely ready.” — Daniel Barber, Chief Executive Officer · 2026-05-14 With a potential filing in weeks, the stock has risen ~14% over the last 90 days, though it sits about 7% below its June high. The upcoming resubmission is the clear catalyst, and the data suggests the company is in a stronger position than at any point since the CRL.